within Pharmacolibrary.Drugs.ATC.C;

model C09CA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.26,
    Cl             = 0.021666666666666667,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0179,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) used primarily for the treatment of hypertension. It is approved for use in adults and pediatric patients to lower blood pressure, thereby reducing the risk of stroke and myocardial infarction.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li>Gregory T Warner, Blair Jarvis,Olmesartan medoxomil.,Drugs,2002<a href='https://pubmed.ncbi.nlm.nih.gov/12076183/'>https://pubmed.ncbi.nlm.nih.gov/12076183/</a></li><li>Xinjing Li, Enpan Mo, Lin Chen,Pharmacokinetics and Bioequivalence Evaluation of 2 Olmesartan Medoxomil and Amlodipine Besylate Fixed-Dose Combination Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions.,Clinical pharmacology in drug development,2022<a href='https://pubmed.ncbi.nlm.nih.gov/35289500/'>https://pubmed.ncbi.nlm.nih.gov/35289500/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09CA08;
